Literature DB >> 11401959

Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation.

M C Kullberg1, A G Rothfuchs, D Jankovic, P Caspar, T A Wynn, P L Gorelick, A W Cheever, A Sher.   

Abstract

We have previously shown that specific-pathogen-free interleukin-10 (IL-10)-deficient (IL-10 KO) mice reconstituted with Helicobacter hepaticus develop severe colitis associated with a Th1-type cytokine response. In the present study, we formally demonstrate that IL-12 is crucial for disease induction, because mice deficient for both IL-10 and IL-12 p40 show no intestinal pathology following H. hepaticus infection. By using monoclonal antibodies (MAbs) to IL-12, gamma interferon (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha), we have further analyzed the role of these cytokines in the maintenance of the Th1 response and inflammation in IL-10 KO mice with established H. hepaticus-induced colitis. Treatment of infected colitic IL-10 KO mice with anti-IL-12 p40 resulted in markedly reduced intestinal inflammation, colonic IFN-gamma, TNF-alpha, and inducible nitric oxide synthase (iNOS) mRNA levels, and H. hepaticus-specific IFN-gamma secretion by mesenteric lymph node (MLN) cells compared to the findings in control MAb-treated mice. Moreover, the diminished pathology was associated with decreased numbers of colonic CD3(+) T cells and significantly reduced frequencies of Helicobacter-reactive CD4(+) Th1 cells in MLN. In contrast, anti-IFN-gamma and/or anti-TNF-alpha had no effect on intestinal inflammation in IL-10 KO mice with established colitis. Using IL-10/IFN-gamma double-deficient mice, we further show that IFN-gamma is not required for the development of colitis following H. hepaticus infection. MLN cells from infected IL-10/IFN-gamma KO animals secreted elevated amounts of IL-12 and TNF-alpha following bacterial antigen stimulation, indicating alternative pathways of disease induction. Taken together, our results demonstrate a crucial role for IL-12 in both inducing and sustaining intestinal inflammation through recruitment and maintenance of a pool of pathogenic Th1 cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401959      PMCID: PMC98456          DOI: 10.1128/IAI.69.7.4232-4241.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni.

Authors:  K F Hoffmann; S L James; A W Cheever; T A Wynn
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

2.  Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice.

Authors:  L Camoglio; A A te Velde; A de Boer; F J ten Kate; M Kopf; S J van Deventer
Journal:  Eur J Immunol       Date:  2000-05       Impact factor: 5.532

3.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

4.  Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions.

Authors:  Z Liu; K Geboes; S Colpaert; L Overbergh; C Mathieu; H Heremans; M de Boer; L Boon; G D'Haens; P Rutgeerts; J L Ceuppens
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

5.  Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice.

Authors:  I J Fuss; T Marth; M F Neurath; G R Pearlstein; A Jain; W Strober
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

Review 6.  Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.

Authors:  P Gionchetti; F Rizzello; A Venturi; F Ugolini; M Rossi; P Brigidi; R Johansson; A Ferrieri; G Poggioli; M Campieri
Journal:  Eur Rev Med Pharmacol Sci       Date:  1999 Jan-Feb       Impact factor: 3.507

7.  Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration.

Authors:  Y P De Jong; M Comiskey; S L Kalled; E Mizoguchi; R A Flavell; A K Bhan; C Terhorst
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

Review 8.  Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.

Authors:  A Raza
Journal:  Microsc Res Tech       Date:  2000-08-01       Impact factor: 2.769

9.  Identification of a novel bacterial sequence associated with Crohn's disease.

Authors:  C L Sutton; J Kim; A Yamane; H Dalwadi; B Wei; C Landers; S R Targan; J Braun
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

10.  Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice.

Authors:  L A Dieleman; A Arends; S L Tonkonogy; M S Goerres; D W Craft; W Grenther; R K Sellon; E Balish; R B Sartor
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

View more
  62 in total

1.  Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene.

Authors:  Katharine H Banner; Christophe Cattaneo; Jean-Loic Le Net; Aleksandar Popovic; David Collins; Jeremy D Gale
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

Review 2.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

3.  Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis.

Authors:  Yohei Okada; Noriaki Maeda; Shoji Takakura; Keiji Miyata; Masahiro Koshiba
Journal:  Inflamm Res       Date:  2011-08-10       Impact factor: 4.575

Review 4.  Host-bacterial symbiosis in health and disease.

Authors:  Janet Chow; S Melanie Lee; Yue Shen; Arya Khosravi; Sarkis K Mazmanian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

Review 5.  Association between Helicobacter spp. infections and hepatobiliary malignancies: a review.

Authors:  Fany Karina Segura-López; Alfredo Güitrón-Cantú; Javier Torres
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

6.  Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid.

Authors:  Mansour Mohamadzadeh; Erika A Pfeiler; Jeffrey B Brown; Mojgan Zadeh; Matthew Gramarossa; Elizabeth Managlia; Praveen Bere; Bara Sarraj; Mohammad W Khan; Krishna Chaitanya Pakanati; M Javeed Ansari; Sarah O'Flaherty; Terrence Barrett; Todd R Klaenhammer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 7.  Immunopathogenesis of inflammatory bowel disease.

Authors:  David Q Shih; Stephan R Targan
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Interleukin 10 protects the brain microcirculation from spirochetal injury.

Authors:  Diana Londoño; Jenny Carvajal; Carolina Arguelles-Grande; Adriana Marques; Diego Cadavid
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

9.  Quantitative trait loci in a bacterially induced model of inflammatory bowel disease.

Authors:  Andrew E Hillhouse; Matthew H Myles; Jeremy F Taylor; Elizabeth C Bryda; Craig L Franklin
Journal:  Mamm Genome       Date:  2011-06-30       Impact factor: 2.957

10.  Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitis.

Authors:  Erin C Steinbach; Taku Kobayashi; Steven M Russo; Shehzad Z Sheikh; Gregory R Gipson; Samantha T Kennedy; Jennifer K Uno; Yoshiyuki Mishima; Luke B Borst; Bo Liu; Hans Herfarth; Jenny P Y Ting; R Balfour Sartor; Scott E Plevy
Journal:  J Immunol       Date:  2014-03-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.